Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 16, 2024
A Study of DCR-STAT3 in Adults With Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 24, 2023
Details : The license agreement aims to develop FT-7051 (renamed P-300), an oral, small molecule CBP/p300 inhibitor program from Novo Nordisk as Pathos’ first clinical-stage asset in its pipeline.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 23, 2023
Lead Product(s) : FT-3171,Inapplicable
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Acquisition
Debiopharm Extends Their DNA Damage Repair Footprint With New Oncology Pipeline Entry
Details : Debiopharm obtains global rights from Novo Nordisk for the development of FT-3171, a small molecule (ubiquitin-specific protease 1) USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 03, 2023
Lead Product(s) : FT-3171,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Etavopivat,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 05, 2022
Lead Product(s) : Etavopivat,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pocenbrodib,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT-7051 is designed to attach to the CBP/p300 bromodomain potently and selectively, which then blocks androgen binding and reduces AR activation. In preclinical studies, FT-7501 demonstrated activity in both prostate cancer models that were sensitive.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Pocenbrodib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olutasidenib,Cytarabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Rigel Pharmaceuticals
Deal Size : $235.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Rigel Pharmaceuticals will develop, manufacture and commercialize FT-2102 (olutasidenib), an oral, small molecule inhibitor of mIDH1 being investigated for the treatment of relapsed/refractory acute myeloid leukemia and ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $2.0 million
February 08, 2022
Lead Product(s) : Olutasidenib,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Rigel Pharmaceuticals
Deal Size : $235.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT-2102 (Olutasidenib) in combination with Vidaza (Azacitidine) is found to be well-tolerated and, yielded durable complete remission in the first Phase 2 combination trial in patients with the mIDH1 form of acute myeloid leukemia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2021
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pocenbrodib,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT-7051 is designed to attach to the CBP/p300 bromodomain potently and selectively, which then blocks androgen binding and reduces AR activation.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 10, 2021
Lead Product(s) : Pocenbrodib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olutasidenib,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021
Details : The Phase 1/2 study is a multicenter, open-label, multi-cohort evaluation of the safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of olutasidenib for patients with AML or myelodysplastic syndrome (MDS) with an IDH1 mutation.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2021
Lead Product(s) : Olutasidenib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable